Aadi Bioscience (AADI)
(Real Time Quote from BATS)
$1.88 USD
+0.04 (2.17%)
Updated Sep 18, 2024 12:00 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Aadi Bioscience, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 109 | 173 | 149 | 43 | 39 |
Receivables | 5 | 2 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 2 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 2 | 2 | 1 |
Total Current Assets | 125 | 180 | 151 | 45 | 40 |
Net Property & Equipment | 5 | 1 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 4 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 0 | 0 |
Total Assets | 132 | 184 | 158 | 45 | 40 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 4 | 6 | 2 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 15 | 8 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 26 | 19 | 15 | 2 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 6 | 6 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 26 | 22 | 2 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 374 | 362 | 279 | 190 | 179 |
Retained Earnings | -269 | -203 | -143 | -147 | -142 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 105 | 158 | 136 | 43 | 37 |
Total Liabilities & Shareholder's Equity | 132 | 184 | 158 | 45 | 40 |
Total Common Equity | 105 | 158 | 136 | 43 | 37 |
Shares Outstanding | 24.50 | 24.40 | 20.80 | 3.10 | 2.70 |
Book Value Per Share | 4.29 | 6.49 | 6.56 | 13.89 | 13.53 |
Fiscal Year End for Aadi Bioscience, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 79 | 88 | 109 | 119 | 135 |
Receivables | 6 | 5 | 5 | 6 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 6 | 6 | 4 | 3 |
Other Current Assets | 2 | 3 | 4 | 4 | 3 |
Total Current Assets | 93 | 103 | 125 | 133 | 145 |
Net Property & Equipment | 6 | 6 | 5 | 4 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 102 | 111 | 132 | 140 | 151 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 6 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 11 | 14 | 12 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 6 | 6 | 6 | 0 |
Total Current Liabilities | 22 | 20 | 26 | 21 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 6 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 21 | 27 | 21 | 20 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 381 | 378 | 374 | 371 | 368 |
Retained Earnings | -302 | -287 | -269 | -253 | -236 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 79 | 90 | 105 | 118 | 131 |
Total Liabilities & Shareholder's Equity | 102 | 111 | 132 | 140 | 151 |
Total Common Equity | 79 | 90 | 105 | 118 | 131 |
Shares Outstanding | 24.50 | 24.50 | 24.50 | 24.50 | 24.40 |
Book Value Per Share | 3.22 | 3.69 | 4.29 | 4.82 | 5.39 |